CHRS Coherus BioSciences, Inc: Earnings per share for the last 12 months

Coherus BioSciences, Inc (CHRS) - corporate logo

This chart of Coherus Biosciences (CHRS) share prices reflects the EPS (TTM) dynamics, which currently stand at 39.20. Coherus Biosciences generates revenue through the sale of antineoplastic agents and biosimilars. Management is actively divesting non-core assets to reduce debt, confirming the transparency of the Loqtorzi rollout. To counter dumping by industry behemoths, the firm is optimizing costs and implementing flexible pricing.

Coherus BioSciences, Inc (CHRS) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

CHRS (Coherus BioSciences Inc.): analytical breakdowns and indicator data

- company stock capitalization data:
Fundamental company valuation:CHRS Coherus
Flagship merchandise of Coherus BioSciences, Inc.

Coherus Biosciences (CHRS) is currently restructuring its product portfolio, strengthening its biosimilar commercialization team while maintaining its scientific core. The 39.20 metric reflects the percentage change in the rolling annual total of earnings per share, revealing the actual profitability trend. This indicator allows investors to distinguish a temporary price drop from a systemic business decline. An analysis of the YoY net income per share growth over the last 12 months confirms the resilience of the financial model.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months